Ataxia With Vitamin E Deficiency is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Ataxia with Vitamin E Deficiency (AVED) is a rare autosomal recessive neurodegenerative disorder characterized by progressive cerebellar ataxia, peripheral neuropathy, and significantly reduced serum vitamin E levels. The disease results from mutations in the TTPA gene (alpha-tocopherol transfer protein), which impairs the body's ability to utilize and transport vitamin E.[1]
AVED is a hereditary ataxia that mimics Friedreich's ataxia in its clinical presentation but is potentially treatable with vitamin E supplementation. The condition was first described in 1981 and is estimated to affect approximately 1 in 500,000 individuals worldwide, though it may be underdiagnosed due to clinical overlap with other ataxias.[2]
AVED is caused by homozygous or compound heterozygous mutations in the TTPA gene located on chromosome 8q13.1. This gene encodes alpha-tocopherol transfer protein (α-TTP), which is responsible for incorporating alpha-tocopherol (the most active form of vitamin E) into very-low-density lipoprotein (VLDL) for distribution to tissues.[3]
More than 40 pathogenic variants have been identified in TTPA, including:
The most common mutation varies by population, with the p.Lys197Asnfs*38 mutation being frequent in North African families.[4]
Vitamin E deficiency in AVED leads to:
The neuropathology shows:
| Symptom | Onset Age | Frequency |
|---|---|---|
| Progressive ataxia | 4-20 years | 100% |
| Areflexia (absent reflexes) | Childhood | 90% |
| Distal weakness | 5-15 years | 80% |
| Dysarthria (slurred speech) | 5-18 years | 85% |
| Head titubation | Childhood | 70% |
| Reduced proprioception | Childhood | 75% |
The progression of AVED follows a characteristic pattern:
Diagnosis is based on:
AVED must be distinguished from:
| Test | Finding |
|---|---|
| Serum vitamin E | Markedly reduced (< 5 μg/mL) |
| Serum cholesterol | Usually normal |
| Brain MRI | Cerebellar atrophy, especially vermis |
| Nerve conduction studies | Axonal peripheral neuropathy |
| Genetic testing | TTPA pathogenic variants |
| ECG | Usually normal (differs from Friedreich's) |
High-dose vitamin E supplementation is the cornerstone of treatment:
With early diagnosis and consistent treatment:
Several clinical trials are investigating:
TTPA knockout mice recapitulate the human disease phenotype and are used to study:
The study of Ataxia With Vitamin E Deficiency has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
This section highlights recent publications relevant to this disease.
Clinical and genetic analysis of a case series of 12 Chinese families with hereditary ataxia. ↩︎
Dietary and lifestyle interventions for the management of hereditary ataxias. ↩︎
A TTPA deletion is associated with retinopathy with vitamin E deficiency in the English Cocker Spaniel dog. ↩︎
Ataxia With Vitamin E Deficiency: Case Series, Vitamin E Therapy Response, Founder Effect, and In Silico Analysis. ↩︎